Trends, lag and characteristics of rare disease drug approval in the USA and China, 1983–2022

Shaohong Wang, Xin Liu, Yuzhen Zou, Yan Tang, Wei Zuo, Rong Jiang, Junmei Shang, Xin Tian, Qingyang Liu, Tingting Xu, Bo Zhang, Shuyang Zhang · 2025

Read Trends, lag and characteristics of rare disease drug approval in the USA and China, 1983–2022 by Shaohong Wang, Xin Liu, Yuzhen Zou, Yan Tang, Wei Zuo, Rong Jiang, Junmei Shang, Xin Tian, Qingyang Liu, Tingting Xu, Bo Zhang, Shuyang Zhang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12750715.txt.

Description

Wang and a team including Zhang compare rare disease drug approvals in the United States and China in twenty twenty-five. China has reformed its drug rules many times over forty years to speed approvals. Rare diseases gained official catalogues in twenty eighteen and twenty twenty-three. The team tracked approvals from nineteen eighty-three to twenty twenty-two.

The United States approved six hundred ninety-three orphan drugs in that span. China approved two hundred one of them, about twenty-nine percent. The lag between United States and Chinese approval shrank a lot over time. In the late twenty tens, the median lag was about one point four years. That is a drop of more than ninety percent from the earliest period. The authors credit regulatory reform and fast track procedures.

Catalog record

CREATORShaohong Wang, Xin Liu, Yuzhen Zou, Yan Tang, Wei Zuo, Rong Jiang, Junmei Shang, Xin Tian, Qingyang Liu, Tingting Xu, Bo Zhang, Shuyang Zhang
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE38 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12750715

Browse the full library · About the Tower of Babel